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Abstract
Background: Turner syndrome (TS) is associated with a neurocognitive phenotype that includes
selective nonverbal deficits, e.g., impaired visual-spatial abilities. We previously reported evidence
that this phenotype results from haploinsufficiency of one or more genes on distal Xp. This
inference was based on genotype/phenotype comparisons of individual girls and women with partial
Xp deletions, with the neurocognitive phenotype considered a dichotomous trait. We sought to
confirm our findings in a large cohort (n = 47) of adult women with partial deletions of Xp or Xq,
enriched for subjects with distal Xp deletions.
Methods: Subjects were recruited from North American genetics and endocrinology clinics.
Phenotype assessment included measures of stature, ovarian function, and detailed neurocognitive
testing. The neurocognitive phenotype was measured as a quantitative trait, the Turner Syndrome
Cognitive Summary (TSCS) score, derived from discriminant function analysis. Genetic analysis
included karyotyping, X inactivation studies, fluorescent in situ hybridization, microsatellite marker
genotyping, and array comparative genomic hybridization.
Results: We report statistical evidence that deletion of Xp22.3, an interval containing 31
annotated genes, is sufficient to cause the neurocognitive phenotype described by the TSCS score.
Two other cardinal TS features, ovarian failure and short stature, as well as X chromosome
inactivation pattern and subject's age, were unrelated to the TSCS score.
Conclusion: Detailed mapping suggests that haploinsufficiency of one or more genes in Xp22.3,
the distal 8.3 megabases (Mb) of the X chromosome, is responsible for a TS neurocognitive
phenotype. This interval includes the 2.6 Mb Xp-Yp pseudoautosomal region (PAR1).
Haploinsufficiency of the short stature gene SHOX in PAR1 probably does not cause this TS
neurocognitive phenotype. Two genes proximal to PAR1 within the 8.3 Mb critical region, STS and
NLGN4X, are attractive candidates for this neurocognitive phenotype.
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Background
Turner syndrome (45, X, TS, monosomy X) is the genetic
disorder resulting from the absence of all or part of one X
chromosome in females. The complex TS phenotype
includes short stature, ovarian failure, and a characteristic
neurocognitive profile [1]. Although severe developmental disorders do not predominate in TS, the risk of selective deficits in certain cognitive domains is substantially
increased. Girls and women with 45, X TS commonly
demonstrate deficits in visual-spatial abilities, visual-perceptual abilities, motor function, nonverbal memory,
executive function and attentional abilities when compared to normal females matched for age, height, IQ, and
socioeconomic status [2-9].
Both hormonal and genetic factors may influence the cognitive development of TS females. Hormonal influences
are attributable to deficient ovarian production of estrogen, androgen, or both. Subtle estrogen effects on motor
function and processing speed and androgen effects on
working memory have been demonstrated [10-12]. However, many of the cognitive deficits characteristic of TS are
consistent across a wide age range, including children as
well as estrogen-replaced adults [4,11,12]. Furthermore,
these deficits are generally not seen in females with premature ovarian failure and intact X chromosomes [13,14],
suggesting a predominant role of genetic factors in the etiology of TS cognitive deficits.
The genetic abnormality in TS is determined by the
absence of one copy of genes on the X chromosome. Most
aspects of the TS phenotype, including the cognitive phenotype, are thought to be due to half-normal gene dosage,
or haploinsufficiency, of X-linked genes that escape inactivation [15,16]. Although one X chromosome undergoes
inactivation in normal females during early embryogenesis, about 15% of all X chromosome genes, mostly situated on the short arm (Xp), remain active to some degree
on both X chromosomes [17]. Some of these genes have
functional Y-linked homologs that are thought to balance
their dosage between males and females. The pseudoautosomal region (PAR1), a 2.6 Mb interval at the tips of the X
and Y short arms, is a plausible location for TS genes
because PAR1 genes are all expressed at diploid dosage in
both males and females [18,19]. One PAR1 gene, SHOX
[Mendelian Inheritance in Man (MIM) 12865], has been
implicated in TS short stature [20]. Whether any PAR1
genes contribute to other aspects of the TS phenotype is
unknown.
One way to deduce the underlying genotype-phenotype
relationships in TS is to compare the phenotypes of individuals missing various portions of one X chromosome in
order to assign specific features to "critical regions." A trait
maps to a region if deletion of that region accounts for the
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variance in that trait. This approach was used to map short
stature to the SHOX gene on Xp [20] and ovarian failure
to regions of the long arm (Xq) [21]. We have previously
applied this phenotype mapping methodology to define
genetic correlates of the cognitive phenotype in children
with TS [22].
We used discriminant function analysis to derive a mathematically defined TS cognitive phenotype to test for association with deletions of specific regions of the X
chromosome [22,23]. The initial results from 34 subjects
with deletions of varying portions of Xp, mapped mostly
by fluorescence in situ hybridization (FISH), identified a
probable association between deletion of the distal ~10
Mb of Xp and the TS neurocognitive phenotype [22].
However, those conclusions relied upon identification of
the TS neurocognitive phenotype in a small number of
individual subjects; the sample was too small to permit
rigorous statistical inference. The TS cognitive phenotype
was defined as a dichotomous measure, rather than a
quantitative trait, using a cutoff score. In addition, the
population was heterogeneous, including both children
and adults, and did not include any subjects with Xq deletions, who commonly receive the TS diagnosis.
In the present study, we attempted to confirm and expand
the initial findings using 47 adult females with nonmosaic deletions distributed along both Xp and Xq. Potential
sources of variation in cognitive outcome have been minimized by including only adults with similar estrogenreplacement status. In this study we treated the TS cognitive phenotype as a quantitative rather than a qualitative
trait and compared the results of women with deletions of
varying portions of the X chromosome to that of 45, X TS
and normal controls. We hypothesized that an association
exists between the defined TS neurocognitive phenotype
and deletion of Xp22.3, which includes the distal 8.3 Mb
of Xp.

Methods
Subjects
This study was approved by the Thomas Jefferson University Human Studies Committee and the UT Southwestern
Institutional Review Board. Informed consent was
obtained from all participants. Subjects, ages 17–55 years,
were recruited from North American genetics and endocrinology clinics. We excluded subjects with sex chromosome mosaicism, ring X chromosomes, clinical features of
autosomal aneuploidy in the case of unbalanced X;autosome translocations, or clinical diagnoses of Goltz [MIM
305600], Aicardi [MIM 304050], or MLS [MIM 309801]
syndromes in the case of Xp22.3 deletions. Subjects with
Verbal IQ (VIQ) < 69 were also excluded since significantly reduced VIQ is atypical for this population and, in
the context of depressed spatial skills, implies generalized
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limitation of intelligence. Subjects with serum gonadotropin levels in the castrate range (≥ twice the upper limit of
normal) and amenorrhea were determined to have ovarian failure. Some of the deletion subjects had normal
menstrual histories and were evaluated in the follicular
phase of their cycle. Subjects with ovarian failure were
receiving standard estrogen replacement therapy (i.e.
cycling with estrogen and progesterone).
Cytogenetic and molecular analyses
Standard Giemsa-banded peripheral blood karyotypes
were obtained for subjects not evaluated cytogenetically
within the previous two years, with particular attention
paid to the X chromosome. Lymphoblastoid cell lines
were derived from blood samples by standard methods
[24]. X inactivation pattern was measured from blood
DNA using the androgen receptor methylation assay [25].
Metaphase spreads from blood or lymphoblastoid cells
were used for FISH as previously described [22,26].

A variety of techniques were used to map deletions,
including FISH [22,26], polymorphic microsatellite markers [27], and array comparative genomic hybridization
(CGH) [28]. Genotyping data were interpreted as
described previously [29]. Briefly, heterozygous markers
were scored as not deleted, and markers showing loss of
heterozygosity or non-inheritance of a parental allele were
scored as deleted. Selected subjects whose deletions were
initially mapped by FISH were restudied with microsatellite markers when parental DNAs became available.
Breakpoints were inferred from data on relatives for subject 105 (blood sample unavailable) whose deletion was
familial. Oligonucleotide array CGH was performed on
male offspring of 430 and 702 known to carry the deletion by Nimblegen Systems, Inc. (Madison, WI) using an
X chromosome tiling array (Catalog B3754001-00-01,
one probe every 340 bp on average) and pooled normal
male reference DNA (Promega Corp., Madison, WI).
Probe signal intensities were averaged over a 4 kilobase
window (~12 adjacent probes) and copy number changes
detected using a circular binary segmentation algorithm
[30]. Map locations of markers are based on the UC Santa
Cruz Genome Browser, March 2006 Human Genome
Assembly.
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ysis used the Mahalanobis distance formula to maximize
the n-dimensional distance between group centroids to
weigh the variables in order to optimally separate the TS
and control generative samples. The resulting formula
yielded the TS cognitive summary (TSCS) score. The components of the TSCS score and the weighting coefficients
are indicated in Table 1. The mean TSCS scores differed
significantly for the TS and control populations (53 ± 17
versus 67 ± 17, P < 0.0001, T-test, df = 195) and there was
no or minimal correlation of TSCS score with age or SES.
Based on an a priori cut-off, the sensitivity and specificity
of the TSCS score in this sample were 0.83 and 0.87,
respectively. The other half of the population formed a
prospective replication sample in which the sensitivity
and specificity of the TSCS score were each 0.78. The formula for the TSCS score was similar to the previously published discriminant function analysis [23] but was
performed on larger populations of TS and control subjects.
Stability of the TSCS score was demonstrated by analysis
of the TSCS score results for a different group of TS subjects (n= 29), evaluated at baseline and again, one year
later. The mean TSCS scores were highly consistent, 48.9
± 16.9 (baseline) and 49.9 ± 16.1 (one year later). The
Pearson correlation of results from the two sets of scores
was r = 0.84, df = 27, P < 0.0001). Thus, the TSCS score has
test-retest reliability and long-term stability with repeat
testing.
Statistical analyses
Results are presented as mean ± standard deviation (SD).
Comparisons among means for more than two groups
were performed using an analysis of variance (ANOVA),
and Tukey's Standardized Range test (Tukey test) was used
for pairwise, post-hoc comparisons. T-tests were also used
when comparisons were performed between two groups
which were not subgroups in the overall ANOVA comparisons. Correlations between age, height and ovarian status
with TSCS score were examined using the Pearson correlation coefficient. Results were considered statistically significant at P < 0.05. All analyses were performed using SAS
version 8.2 (Cary, NC).

Results
Derivation of the TSCS score
All cognitive evaluations were administered and scored by
psychometricians who were unaware of specific karyotype
results. We first performed discriminant function analysis
using the results of the battery of cognitive tests (Table 1)
on populations of nonmosaic, 45, X TS subjects (n = 94)
and age-, VIQ-, and socioeconomic status (SES)-matched
normal female controls (n = 103), ages 17.0–55.0 years.
The populations were randomly divided in halves to form
generative and prospective replication samples. The anal-

Study population
The genetic study population included 47 women, ages
17–55 years, with partial monosomy for Xp or Xq due to
terminal or interstitial deletions, unbalanced translocations, or other rearrangements (Table 2). Comparison
groups included adult women with 45, X TS and normal
female adult controls. These were mostly the same subjects used in the construction and testing of the TSCS
score, which was described above.
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Table 1: Components of the TSCS. Weighting coefficients of each variable in the discriminant function are indicated. SS denotes
standardized score.

Cognitive Domain

Variable

Ref.

Weighting Coefficient

Visual-Motor Ability

Rey-Osterrieth Complex Figure-copy
Developmental Test of Visual-Motor Integration [SS]
WAIS-III: Object Assembly [SS]
WAIS-III: Block Design [SS]
WAIS-III: Coding/Digit Symbol [SS]
The Pursuit Rotor Dominant Time Off Target
The Pursuit Rotor Distance
Judgment Of Line Orientation [# Correct]
Money Street Map [Errors Towards]
WAIS-III Picture Completion [SS]
Kaufman Gestalt Closure [% Correct]
The Visual Object and Space Perception Battery-Memory Span [SS]
Test of Facial Recognition [# correct]
The Wechsler Memory Scale-R: Visual Memory [SS]
Rey-Osterrieth Complex Figure – Immediate Recall
Rey-Osterrieth Complex Figure – Delayed Recall
Warrington Memory Test (Faces) [# correct]
WAIS-III: Digit Span-Backwards [SS]
WAIS-III: Arithmetic [SS]
WIDE Range Achievement Test-3-Arithmetic [SS]
Test of Variables of Attention 2nd [Commission errors]
Matching Familiar Figures [# correct]
Verbal Fluencies: Phonemic [# correct]
Verbal Fluencies: Semantic [# correct]
Rey-Osterrieth Complex Figure – Organization
The Tower of Hanoi

[51, 52]
[53]
[54]
[54]
[54]
[55]
[55]
[56]
[57]
[54]
[58]
[59]
[60]
[54]
[51, 52]
[51, 52]
[59]
[54]
[54]
[61]
[62]
[63]
[64, 65]
[64, 65]
[51, 52]
[66]

1.06057
0.31963
-1.47231
0.98230
-1.47952
0.07761
7.62332
-0.66818
3.35712
-0.22349
0.17538
0.72039
4.22581
2.65698
-0.09704
-0.08993
1.66476
-1.22922
-1.09126
0.72213
-2.12936
0.02191
0.45404
0.24121
-0.71923
0.02541

Spatial-Perceptual Ability

Spatial-Relational Memory

Working Memory

Attention-Impulse Control
Executive Function

The groups (partial monosomy for Xp or Xq, 45, X TS, and
normal controls) were well matched for age (Table 3). The
study population (partial X deletions) included Caucasian
(39), African-American (2), Hispanic (4), and Other (2).
Six subjects were members of kinships (430, 428 and 175,
174 were mother and daughter pairs; 105, 315 were a sibling pair. All other subjects were unrelated.
X chromosome deletions of the 47 subjects with partial
monosomy X are indicated schematically in Figs. 1 and 2.
Fifteen of these subjects were previously reported [26,29].
Based on combined karyotype and molecular analyses, 30
subjects had simple terminal deletions, 4 had interstitial
Xq deletions, and 13 had complex rearrangements, mostly
unbalanced translocations.
Phenotypes
Table 2 shows phenotypic data for the 47 individual partial monosomy X subjects, including height z-score, ovarian status, and X inactivation status. We calculated the
mean TSCS scores for four subgroups: subjects with Xp
deletions; subjects with Xq deletions; subjects with 45, X
TS; and normal controls. We also examined seven adult
subjects who carried SHOX point mutations (Table 3).

The mean TSCS scores (Table 3; Fig. 3A) differed significantly among the six groups: five with X chromosome or
SHOX abnormalities and the controls (P < 0.0001,
ANOVA, df = 279). The mean TSCS score of the Xp deletion group was similar to that of the 45, X TS group and
differed from that of the Xq and control groups (P < 0.05,
Tukey test). Thus, deletion of Xp may be necessary and
sufficient for the defined TS neurocognitive phenotype. By
contrast, it appears that Xq deletions did not affect cognitive outcome, since mean TSCS score in this group was
similar to that of controls. Xq deletions did not all overlap
(Fig. 1). However, the mean TSCS score of just subjects
with overlapping terminal Xq deletions (69.5 ± 21.3, n =
15) was also similar to controls (P > 0.05, T-test, df = 117).
Eight of the Xp deletion subjects had unbalanced translocations, and segmental trisomy could affect their phenotype. However, their mean TSCS score was 56.1 ± 18.2,
very similar to that of all other Xp deletion subjects (P =
0.64, T-test, df = 26).
Although all subjects with ovarian failure were receiving
estrogen replacement at the time they were studied, it is
possible that early ovarian failure could have long-term
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Table 2: Cytogenetic and phenotypic data for subjects with X chromosome deletions.
Subject

age (yr)

ovarian failure

karyotype

height SD score

X inactivation ratio

-2.01
-2.59
-2.2
-1.10
-0.82
0.44
-2.4
-2.39
-0.70
-0.75
-2.77
-1.68
-0.61
-1.68
-3.24
-2.25
-3.2
-0.8
-2.5
-1.1
-2.4
-3.42
-2.2
-1.1
-2.8
-3.9
-3.19
-3.18

57:43
71:29
66:34
61:39
51:49
100:0
not informative
92:8
65:35
100:0
93:7
75:25
60:40
89:11
68:32
100:0
100:0
100:0
ND
100:0
100:0
100:0
100:0
ND
100:0
100:0
100:0
100:0

-0.86
3.24
3.17
-2.22
0.35
2.9
0.73
-2.18
-2.45
-1.98
-1.38
-1.7
-1.53
0.88
-0.73
-1.72
1.37
0.53
0.42

100:0
not informative
100:0
100:0
100:0
100:0
100:0
not informative
100:0
100:0
100:0
100:0
100:0
100:0
100:0
100:0
100:0
100:0
100:0

Xp deletions
447
174
175
482
428
430
879
746
298
157
217
702
466
439
451
884
144
46
122
71
211
324
539
111
85
109
315
105

30
22
40
28
20
47
38
47
44
42
29
39
49
31
40
43
36
34
17
20
20
54
23
20
45
46
23
31

no
no
no
no
no
no
no
no
no
no
no
no
no
yes
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes

46, XX
46, X, der(X)t(X;acrocentric) (p22.3;p11.2)mat
46, X, der(X)t(X;acrocentric) (p22.3;p11.2)
46, X, del(X)(p22.33)
46, X, del(X)(p22.33) in affected relative
46, X, del(X)(p22.33)
46, XX in affected relative
46, X, del(X)(p22.3)
46, X, del(X)(p22.33p22.33) in affected relative
46, X, del(X)(p22.31p22.33)
46, X, der(X)t(X;Y)(p22.3?1;q11.2) .ish der(X)KAL+STS+DYZ1+DYZ3-DYZ246, XX
46, X, add(X)(p22.31)
46, X, der(X)t(X;Y)(p22.3;q11.2)
46, X, der(X)t(X;Y)(p22.3;q11.2)
46, X, der(X)t(X;X)(p22.1;q24)
46, X, del(X)(p22.1)
46, X, del(X)(p21.2)
46, X, del(X)(p21.2)
46, X, del(X)(p11.2)
46, X, del(X)(p11.23)
46, X, del(X)(p11.2)
46, X, del(X)(p11.22)
46, X, del(X)(p11.21)
46, X, del(X)(p11.2)
46, X, del(X)(p11.1)
46, X, der(X)t(X;1)(p11;q44)mat
46, X, der(X)t(X;1)(p11;q44)mat
Xq deletions

495
383
340
403
785
140
173
475
162
540
218
139
184
314
172
192
207
438
164

19
24
26
32
37
37
48
20
40
18
35
24
31
32
34
29
44
40
38

yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
no
yes
yes
yes
yes
no
no

46, X, del(X)(q21.1)
46, X, der(X), t(X, X)(q13.1;p11.21)
46, X, rec(X)dup(Xp), inv(X)(p21q21)
46, X, del(X)(q21.2)
46, X, del(X)(q22.2)
46, X, del(X)(q21.2)
46, X, del(X)(q13q27.2)
46, X, del(X)(q21)
46, X del(X)(q21.2)
46, X, der(X)t(X;Y)(q22;q11.2) .ish der(X)t(X;Y)(wcpX+, wcpY+)
46, X, del(X)(q22)
46, X, del(X)(q22)
46, X, del(X)(q24)
46, X, del(X)(q25)
46, X, der(X)t(X;13)(q22.3;q14.1) .ish der(X)t(X;13)(wcpX+;wcp13+)
46, X, del(X)(q21.2, q26)
46, X, del(X)(q22.3;q24)
46, X, del(X)(q24q26.1)
46, X, del(X)(q24q26)

effects on cognitive outcome. Both Xp and Xq deletion
groups were heterogeneous for ovarian failure, so we
tested for an association between this phenotype and
TSCS score among all 47 subjects. The mean TSCS score of
subjects with or without ovarian failure did not differ significantly, and in fact trended toward a higher score in
subjects with ovarian failure (64.3 ± 4.4, n = 27 versus
52.8 ± 4.3, n = 20; P = 0.07, T-test, df = 45). Seventeen of
the subjects without ovarian failure had Xp deletions;

their mean TSCS score was 51.9 ± 19.7, which was similar
to the other Xp deletion subjects (P = 0.7, T-test, df = 26).
TS neurocognitive deficits are consistent across a wide age
range. There was no significant correlation between age
and TSCS score (Pearson r = 0.006, P > 0.9, df = 45)
among our 47 subjects with partial X deletions.
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Table 3: Mean age, height standard deviation score, and TSCS score of subjects grouped according to X chromosome abnormality.
Data shown are mean ± standard deviation.

n Age, yr
45, X
controls
Xp deletion
<Xp22.3
>Xp22.3
Xq deletion
SHOX point mutations

127
104
28
15
13
19
7

33.0 ± 10.4
29.8 ± 9.7
34.1 ± 10.7
36.3 ± 9.1
31.7 ± 12.2
32.4 ± 8.3
42.7 ± 20.2

Having found the TSCS score associated with deletion of
Xp and not Xq, we attempted to narrow the associated
region. We calculated the mean TSCS score for the 15 subjects whose deletions were limited to Xp22.3 (up to but
not including the KAL1 gene at 8.3 Mb) versus the populations of 45, X TS and controls (Fig. 3B). The mean TSCS
score was significantly lower in the population deleted for
only Xp22.3 compared to the normal control population
(P < 0.05, Tukey test, df = 243) and was similar to that of
the TS population (P > 0.05, Tukey test, df = 243)
The known TS short stature gene SHOX is located in
Xp22.3. To determine if SHOX might also influence cognition, we evaluated the relationship between stature,
deletion of SHOX, and TSCS score. There was a correlation
between TSCS score and height among the whole population of Xp and Xq deletion subjects (Pearson r = 0.3, P <
0.04, df = 45). However, there was no significant relationship between TSCS score and height among subjects missing SHOX (Pearson r = 0.12, P > 0.56, df = 5). As noted
above, subjects with Xp deletions >Xp22.3, with mean
height SDS -2.5, showed a mean TSCS score similar to that
of subjects with deletions limited to Xp22.3, with mean
SDS -1.6 (Table 3). The correlation between height and
TSCS score observed among all Xp and Xq deletion subjects is likely due to Xp22.3 deletions that encompass
both SHOX and the cognitive locus rather than a causal
association of stature per se on cognition.
In addition, we determined the TSCS scores for seven subjects with loss-of-function SHOX point mutations, six
with SHOX haploinsufficiency (dyschondrosteosis) and
one with complete absence of SHOX (an 84-year old
woman with Langer mesomelic dysplasia due to compound heterozygosity) [31]. If SHOX haploinsufficiency
was responsible for the neurocognitive phenotype, their
mean TSCS score should be lower than that of controls
and similar to that of the 45, X TS population. The mean
TSCS score of the seven SHOX mutation carriers was similar to that of controls but was not significantly different
from that of the 45, X TS population (Table 3, P >0.05,
Tukey test, df = 279) due to the small sample size of the
SHOX group.

Height SD score

TSCS score

-2.7 ± 1.1
0.1 ± 1.0
-2.1 ± 1.1
-1.6 ± 1.0
-2.5 ± 1.0
-0.2 ± 1.9
-2.7 ± 1.6

58.3 ± 17.5
68.7 ± 17.5
53.1 ± 20.8
54.6 ± 22.0
51.3 ± 20.2
68.7 ± 20.4
67.0 ± 11.5

Refined mapping of Xp22.3 deletions
We fine-mapped deletion breakpoints in the 15 subjects
with deletions limited to Xp22.3 (Fig. 1, boxed) using
additional FISH probes and/or polymorphic microsatellite markers. The smallest deletion (in subject 447) was
mapped using a somatic cell hybrid as described elsewhere [29]. Fig. 2A shows the markers used for mapping
and the extent of distal Xp deletions in relationship to the
cytogenetic and physical maps of this region of the X chromosome and genes annotated in the RefSeq database
[32].

We used array comparative genomic hybridization (CGH)
using an X-chromosome specific tiling oligonucleotide
array (Nimblegen Systems, Inc.) to confirm and refine the
mapping of two deletions associated with mental retardation in male relatives (Fig. 2B). The deletion in subjects
428 and 430, mapped in male relative 429, was visible
cytogenetically (Table 2), despite being limited to pseudoautosomal sequences. The deletion was larger in subject
702, spanning the STS gene, and was associated with Xlinked ichthyosis in her son (701); the mother's deletion
was missed by conventional karyotyping (Table 2). In
both cases, CGH data were consistent with the results
from FISH and genotyping analyses.
Deletion breakpoints were distributed throughout
Xp22.3, without any obvious recombination hotspots
(Fig. 2A). Six breakpoints fell within the Xp-Yp pseudoautosomal region (PAR1). The smallest deletion, in subject
447, encompassed coding sequences of only four genes:
PLCXD1, GTPBP6, PPP2R3B, and SHOX. This subject,
who was ascertained on the basis of dyschondrosteosis,
had a TSCS score of 43.6. Other subjects with PAR1 deletion breakpoints had TSCS scores of 56.1, 21.5, 71.9,
63.9, and 28.1. While the mean for these six subjects differed from that of normal controls (47.5 ± 20, n = 6 vs.
68.7 ± 17.5, n = 104, P = 0.02, T-test, df = 108), we interpret this result from a small cohort cautiously.
X inactivation
We tested the pattern of X inactivation in blood DNA
from our subjects to see if nonrandom X inactivation
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Figure
Schematic
1 depiction of partial X deletions
Schematic depiction of partial X deletions. Black bars indicate nondeleted regions of the X chromosome; gray bars
denote regions of uncertainty between FISH probes. Deletions are indicated by absence of bars. Locations of FISH probes on
cytogenetic and physical maps is shown on the left. Xp22.3 deletion breakpoints shown in greater detail in Fig. 2 are boxed.

might play a role in the neurocognitive phenotype. Fortyfour of 47 subjects tested were informative for the androgen receptor polymorphism used for the inactivation
assay. All informative subjects with deletions extending
beyond Xp22.3 had completely skewed X-inactivation,
with the deleted X presumably inactive (Table 2). By contrast, 11 of the 15 subjects whose deletions were limited
to Xp22.3 (Fig. 1, box) had inactivation patterns ranging
from 50:50–90:10, and only four showed >90% skewing
(Table 2). As previously noted, the distributions of TSCS
scores did not differ between subjects with deletions limited to Xp22.3 versus subjects with larger Xp deletions
(Fig. 2B), although the two groups had very different proportions of skewed inactivation. Thus X inactivation skewing did not seem to affect the TSCS score.

Discussion
An earlier descriptive study suggested that Xp22.3 contains one or more genes that influence cognitive ability in
Turner syndrome [22]. The current results provide additional support for this hypothesis. The strength of the conclusion is based on a larger, all adult study population
that included both Xp and Xq deletion subjects, with uniform estrogen replacement status for those with ovarian
failure. Additionally, the previous study defined a critical
region by determining the minimal overlapping deletion
among a few individuals with the TS neurocognitive phenotype, assigned as a dichotomous trait. The present study
used a quantitative measure of the TS neurocognitive phenotype, the TSCS, to test for associations with deletions,
reducing error due to variability of individual results.
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Figure 2
Refined
mapping of Xp22.3 deletions
Refined mapping of Xp22.3 deletions. a. Positions of microsatellite and FISH markers used to map breakpoints are indicated below ideogram. Black bars denote nondeleted X chromosome segments; gray bars denote segments whose status is
uncertain. Positions of RefSeq http://www.ncbi.nlm.nih.gov/RefSeq annotated genes [32]) are indicated above physical map
scale. Marker and gene locations are from the UC Santa Cruz Genome Browser http://genome.ucsc.edu, March 2006 (hg18)
assembly. b. High resolution mapping of deletions in subject 429 (son of 430) and subject 701 (son of 702) by array comparative genomic hybridization using an X chromosome tiling array. Each dot represents mean log2 signal intensity ratio of probes
within consecutive 4000 bp intervals.
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Figurescores
TSCS
3
of subjects according to deletion
TSCS scores of subjects according to deletion. a. Comparison of mean TSCS scores of subjects with any Xp deletion,
any Xq deletion, TS, and controls. b. Comparison of mean TSCS scores of subjects with Xp22.3 deletions, TS, and controls.
Data shown are mean+SD. *P < 0.05, Tukey's test.

The TSCS score is a composite, quantitative summary that
partially describes the TS cognitive phenotype. For each
individual, the score represents a weighted pattern of performance on a number of cognitive tests that assess multiple clinical domains. Therefore, the mean TSCS score for
a group is an average of performance on this composite
measure. As with all computed means, the mean TSCS
score is not meant to reflect a typical performance but
rather the mean of performances by individuals in that
population that may contain both typical subjects and
atypical subjects. There is overlap in TSCS scores among
the TS and control populations. However, the difference
in the means is statistically significant (P < 0.001). This
overlap in TSCS scores indicates that many TS subjects
function within the normal range (mean ± 2 SD for controls). If there were distinct and complete separation of
both populations in any cognitive trait, then discriminant
function analysis would not be necessary. This cognitive
result is similar to the findings for the height deficit in TS.
Although there are some TS subjects whose height is in the
normal range, the mean height is significantly reduced in
TS [1].
The mean TSCS score from 28 women with overlapping
Xp deletions of varying size was similar to that of 45, X TS
women and differed significantly from that of controls
and women with Xq deletions (Fig. 3A). Their overlapping Xp deletions all included Xp22.3, the region previously hypothesized to affect TS cognition. We therefore
investigated the mean TSCS score of the 15 subjects whose
deletions were restricted to this interval (<Xp22.3). Their

mean TSCS score was also similar to that of 45, X TS subjects and differed significantly from that of controls (Fig.
3B). Larger Xp deletions (>Xp22.3) were not associated
with further reduction in mean TSCS score or increased
individual variability in performance (Fig. 3B, Table 3).
This supports the conclusion that deletion of Xp22.3 may
be sufficient for producing this aspect of the neurocognitive profile in TS.
Previous studies have shown that the likelihood of ovarian failure in patients with terminal Xp deletions is
directly related to the size of the deletion [26,33]. Our
data also show this relationship. The mean TSCS score of
Xp deletion subjects without ovarian failure was similar to
that of 45, X TS subjects, suggesting that distinct Xp loci
contribute to ovarian failure and neurocognitive deficits
in TS.
Using an expanded panel of FISH and microsatellite
markers, and in two cases CGH, we mapped the associated interval to an 8.3 Mb region of Xp22.3 containing
approximately 30 genes. It is interesting that a deletion
limited to the pseudoautosomal region in subject 430 was
associated with mild developmental delay in her son. This
is surprising, since haploinsufficiency of the entire pseudoautosomal region does not usually cause global developmental delay in females. Possible explanations include
unmasking of a recessive Y pseudoautosomal allele, gender-specific effects, or coincidence. The boy did not
undergo detailed cognitive testing.
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While it appears that deletions limited to pseudoautosomal sequences may be sufficient to reduce the TSCS
score, as previously hypothesized, this conclusion is tempered by the fact that two of these deletions were due to
unbalanced Xp;Yq translocations, and Yq heterochromatin could exert position effects on nearby genes such as
NLGN4X [MIM 300427]. The lack of effect of Xq deletions
on the mean TSCS score suggests that the phenotype is
specific for deletion of Xp22.3 rather than a nonspecific
manifestation of aneuploidy or ovarian failure, which
showed no correlation with TSCS score.
Several aspects of the Xp22.3 region are noteworthy. Deletions limited to Xp22.3 usually manifest short stature
rather than the full TS phenotype and are associated with
variable patterns of X inactivation, whereas larger deletions are associated with nonrandom inactivation of the
deleted X chromosome [34]. Patients with Goltz, Aicardi,
or MLS syndrome, who may show deletions limited to
Xp22.3 with highly skewed inactivation [34], were
excluded from our study population. Most of our subjects
with deletions limited to Xp22.3 did not show highly
skewed inactivation. Subjects with larger Xp deletions or
Xq deletions generally showed nonrandom inactivation,
presumably of the deleted X chromosome. The TSCS score
distributions were similar for subjects with deletions limited to Xp22.3 and non-skewed inactivation and subjects
with larger Xp deletions and skewed inactivation. Furthermore, the TSCS scores of subjects with Xq deletions, all of
whom showed highly skewed inactivation, differed from
those of subjects with Xp deletions. Thus, TSCS score was
not related to pattern of X inactivation.
Most of the 30 or so genes in the Xp22.3 critical region
(Table 4) escape X inactivation, and many have Y-linked
homologs, suggesting that they are dosage sensitive [17].
Functional studies of genes in this region using animal
models are hindered by the apparent absence of almost
the entire region in mouse and rat, except for two genes,
PRKX [MIM 300083] and STS [MIM 308100] [19].
STS encodes steroid sulfatase, deficiency of which causes
X-linked ichthyosis [35]. Mouse Sts has been implicated
in modulating neurosteroid levels and thus GABAA receptor function [36]. Mouse Sts is pseudoautosomal and
therefore dosage sensitive, and 39, X mice lacking one
copy of Sts show altered GABAA receptor expression [37].
These mice also show reduced visuospatial attention [38].
Restoration of Sts diploid dosage by a truncated sex chromosome carrying the pseudoautosomal region and a
small number of X-linked genes normalized GABAA receptor expression and rescued the visuospatial attention deficit [37,38]. The investigators concluded that
haploinsufficiency of a pseudoautosomal gene, possibly
Sts, is responsible for visuospatial attention deficits in 39,

http://www.behavioralandbrainfunctions.com/content/3/1/24

X mice and perhaps analogous neurocognitive deficits in
humans with TS.
Other genes in the Xp22.3 region that have been linked to
cognitive phenotypes include VCX3A and NLGN4X.
VCX3A [variable charged X-linked gene 3A, MIM 300533]
belongs to a gene family with multiple closely related
members on both the X and Y chromosome. VCX3A was
proposed to be involved in cognition on the basis of overlapping Xp22.3 deletions associated with mental retardation in a few males [39]. However, a subsequent study
found that only one out of seven males in a family with
icthyosis due to a microdeletion that included VCX3A and
VCX [MIM 300229] had mental retardation [40]. Furthermore, expression of human VCX genes is restricted to
male germ cells [41].
NLGN4X, also in Xp22.3, encodes a neuroligin, or neural
cell adhesion molecule, widely expressed in brain that
escapes inactivation and has a functional Y homolog
[17,42]. Overexpression of the protein in cultured hippocampal neurons has been shown to stimulate formation of
presynaptic terminals [43]. Frameshift and nonsense
mutations in NLGN4X have been linked to Asperger syndrome/autism [MIM 300495, 300497] [44] and X-linked
mental retardation [MIM300495] [45]. Although cognitive effects of reduced NLGN4X dosage have not been
described in female carriers of these mutations, autistic
features have been described as part of the 45, X TS neurocognitive phenotype [46], and three females with autism
and deletions of distal Xp encompassing NLGN4X have
been reported [47]. However, none of our subjects carried
a diagnosis of autism spectrum disorder, and the relationship of TSCS results and autistic features is not clear. The
TSCS score is based on performance on cognitive tests and
therefore has no direct relationship to autistic behavior.
However cognitive impairment on visual-perceptual and
spatial processing tasks may be related to increased risk of
social problems and altered interpersonal relationships.
Our study has several limitations. First, nonmosaic partial
X chromosome deletions are rare. In order to obtain sufficient sample size for statistical comparisons, we included
eleven subjects with unbalanced translocations (eight
with Xp deletions and three with Xq deletions). While
none of these subjects had any obvious features of autosomal trisomy, presumably due to spread of X inactivation to the autosomal segment, we cannot exclude the
possibility of cognitive effects. However, the mean TSCS
score of the unbalanced translocation subjects with Xp
deletions was very similar to that of all Xp deletion subjects. Similarly, because the number of Xq deletion subjects was small, we included subjects whose deletions did
not all overlap. This deletion heterogeneity could mask an
effect of a locus in Xq. However, the mean TSCS score of
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Table 4: RefSeq genes in critical region.

Gene name

RefSeq accession

Product/function

PLCXD1
GTPBP6
PPP2R3B
SHOX
CRLF2
CSF2RA
IL3RA
SLC25A6
CXYorf2
ASMTL
P2RY8
DXYS155E
ASMT
DHRSX
ZBED1
CD99
XG
GYG2
ARSD
ARSE
ARSH
ARSF
MXRA5
PRKX
NLGN4X
VCX3A
HDHD1A
STS
VCX
PNPLA4
VCX2

NM_018390
NM_012227
NM_199326
NM_000451
NM_001012288
NM_006140
NM_002183
NM_001636
NM_025091
NM_004192
NM_178129
NM_005088
NM_004043
NM_145177
NM_004729
NM_002414
NM_175569
NM_003918
NM_001669
NM_000047
NM_001011719
NM_004042
NM_015419
NM_005044
NM_020742
NM_016379
NM_012080
NM_000351
NM_013452
NM_004650
NM_016378

phospholipase
GTP-binding protein-like
phosphatase regulatory subunit
transcription factor/chondrocyte growth
cytokine receptor-like
cytokine subunit
interleukin 3 receptor subunit
mitochondrial adenine nucleotide translocator
hypothetical protein
acetylserine O-methyltransferase-like
G-protein coupled purinergic receptor
novel protein
acetylserine O-methyltransferase
dehydrogenase/reductase
Ac-like transposable element
cell surface antigen
cell surface antigen
glycogenin
arylsulfatase
arylsulfatase (chondrodysplasia punctata)
arylsulfatase
arylsulfatase
adlican
protein kinase; kidney development
neuroligin 4; see text
germ cell protein; see text
haloacid dehalogenase-like hydrolase domain
steroid sulfatase; see text
germ cell protein; see text
phospholipase
germ cell protein; see text

just the subjects with terminal Xq deletions was similar to
controls. Our results strongly support a TS neurocognitive
locus in Xp but do not absolutely exclude a neurocognitive effect of deletion of Xq.
There was ascertainment bias toward ovarian failure, particularly for subjects with Xq deletions, although this
aspect of the TS phenotype did not show any correlation
with TSCS score. Although the study included only adults,
the age range was relatively broad (17–55 years). However, age did not correlate with TSCS score either. Because
parental DNAs were not available for most of the subjects,
we could not address any possible imprinting effect, as
has been claimed for social-behavioral aspects of the TS
cognitive phenotype [48].
As with any complex trait, the presence and severity of the
TS neurocognitive phenotype is variable. This study used
discriminant function analysis, a relatively uncommon
method of defining cognitive phenotype. This method
was used because it allows a quantitative approach to cog-

nition using a group of subjects who, though similar, have
a moderate degree of cognitive heterogeneity. There is
clearly overlap between the distributions of TSCS scores of
45, X TS versus controls: some controls have lower TSCS
scores than the 45, X average, and some 45, X TS subjects
have higher TSCS scores than the control average. Because
of this overlap, the ability to infer genotype/phenotype
correlations based on individual subjects is limited. For
this reason, we based our conclusions on mean TSCS
scores of groups of subjects with similar deletions. This
approach does not require that every individual deleted
for the cognitive locus manifest the identical cognitive
phenotype.
The TSCS reflects performance in multiple cognitive
domains, and includes visual-motor tasks, visual-perceptual tasks, executive function/attention tasks and memory
tasks. Given the complex TS cognitive phenotype in TS, it
is not expected that the absence of a single gene leads
directly to this complete phenotype or even to a specific
cognitive trait associated with TS. Therefore, it is unlikely
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that within Xp22.3 there is a specific gene that codes for a
specific cognitive dysfunction. Rather, absence of this
gene most likely affects a biological activity that is intimately involved in the development of the phenotype,
manifesting as a complex and nonfocal neurocognitive
phenotype. The TSCS is still an incomplete representation
of the TS cognitive phenotype. There are other cognitive
features, including motor and social function not
included in the TSCS. Therefore, it is likely that the TS cognitive phenotype is due to multiple cognitive determinants and multiple genes, each contributing to the
phenotypic variance.
Molko et al. [49] described cerebral structural changes in
TS compared to female controls. These regions included
the right intrapatietal sulcus and bilateral superior temporal sulci. These regions have classically been associated
with spatial-perceptual ability and spatial-relational
memory. Dysfunction in these cognitive domains is part
of the TS cognitive phenotype. Therefore, it is reasonable
to speculate that the cognitive change associated with
deletion of Xp22.3 may be mediated through structural
changes in these anatomic regions.
These results are clinically relevant for patients with partial X chromosome deletions. TS is classically defined as
monosomy X with typical physical and cognitive phenotypes. Early karyotype/phenotype correlations studies
implicated loss of the short arm in growth failure. The discovery of the SHOX gene suggested a continuum between
idiopathic short stature [MIM 300582], due to deletion of
only the SHOX gene, and TS, which could be viewed as a
contiguous gene deletion syndrome. For purposes of diagnosis and treatment, the distinction has been made
between deletions smaller than Xp22.3 associated only
with short stature (idiopathic short stature or dyschondrosteosis [MIM 127300]) and larger Xp deletions associated with both short stature and ovarian failure (TS) [50].
However, it must now be recognized that patients with
Xp22.3 deletions, regardless of diagnosis, are at risk for TS
neurocognitive deficits and should be evaluated accordingly. Furthermore, in the absence of mosaicism, the risk
of these cognitive deficits in patients with Xq deletions is
low.

Conclusion
In summary, haploinsufficiency of genes located in
Xp22.3 appears to cause at least part of the multifaceted
cognitive phenotype of 45, X TS, as indexed by TSCS score.
This critical region contains 30 or so genes. The lack of
murine orthologs of most of these genes (with the exception of STS and PRKX) and the limitations of mouse models for complex human cognitive abilities precludes
identifying the causative gene by knockout models. An
alternative approach is to test for association between
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genetic variation in Xp22.3 genes and the TSCS in 45, X TS
subjects. In addition, high resolution genomic technologies such as array comparative genomic hybridization
may detect submicroscopic deletions associated with TS
cognitive deficits that would identify the causative
gene(s), as was the case for short stature due to SHOX
deletion. Identification of the TS cognitive gene would
facilitate early diagnosis and intervention in individuals
with the associated neurocognitive deficits.
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